Literature DB >> 33472486

Peritoneal well-differentiated papillary mesothelioma associated with infertility in a 37-year-old woman.

Bo Pang1,2, Cong Hu2,3, Qian Liu3, Jinyu Yu4, Zhentong Wei5, Xiaowei Yu3.   

Abstract

Well-differentiated papillary mesothelioma (WDPM) is an uncommon mesothelial tumor. The lesions may be single or multiple and usually behave in a benign or indolent fashion, sometimes persisting for many years. In the present case, a 37-year-old woman had experienced primary infertility for 12 years, and a diagnostic laparoscopy was performed. Approximately 200 mL of dark red, free fluid in the pelvis and more than 10 yellow-white nodules on the surface of the right round ligament, sacrum ligament, right fallopian tube, and both sides of the uterus were found. A lesionectomy was performed and immunohistochemical markers indicated WDPM with adenomatoid tumor. The patient was monitored by computed tomography and serum CA125 (cancer antigen 125) levels for 49 months with no recurrence. WDPM and adenomatoid tumor are both benign tumors of mesothelial origin. Because of the lack of effective radical treatment, regular follow-up is sufficient. However, the effects of estrogen and progesterone on WDPM and adenomatoid tumors during ovulation or pregnancy remains unclear. Although WDPM is not life threatening, a strategy to fulfill the fertility requirements of women with this condition is a new challenge for infertility doctors.

Entities:  

Keywords:  Well-differentiated papillary mesothelioma; adenomatoid tumor; assisted reproductive technology; fertility; infertile; pregnant

Mesh:

Year:  2021        PMID: 33472486      PMCID: PMC7829537          DOI: 10.1177/0300060520986680

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


Background

Well-differentiated papillary mesothelioma (WDPM) is an abnormal mesothelial proliferation most commonly encountered as an incidental finding in the peritoneal cavity, pericardium, or tunica vaginalis. WDPM occurs within a wide age range, is especially found during the reproductive years, and affects more women than men.[1] The lesions may be single or multiple but, by definition, do not invade the underlying stroma and usually behave in a benign or indolent fashion, sometimes persisting for many years.[2,3] Patients with WDPM are mostly asymptomatic; thus, WDPM is rarely seen in patients with infertility.

Case Report

Four years prior to this reporting, a 37-year-old woman (gravida 0) consulted our Department of Gynecology for primary infertility that she had experienced for 12 years. Physical examination was normal, ovulation occurred in the natural cycle, hysterosalpingography revealed unilateral patency, and transvaginal ultrasound revealed chylous echo pelvic effusion, measuring 47 mm anterior and 46 mm posterior to the uterus. Her serum CA125 level was 43.53 U/mL (normal range: 0–35 U/mL). Before proceeding with assisted reproductive technology, we performed a diagnostic laparoscopy. In the pelvis, approximately 200 mL of dark red, free fluid was observed, along with more than 10 yellow-white polypoid nodules or papillary formations, with a maximum diameter of 1.5 cm, on the surface of the round ligament, sacrum ligament, right fallopian tube, and both sides of the uterus. No obvious abnormality was found in the appearance of the left fallopian tube and bilateral ovaries, whereas the surface of the right fallopian tube was covered in miliary tumors of different sizes. The serous surface lesions of the fallopian tube were removed and sent to the lab for pathological analysis. The pathology report indicated WDPM with adenomatoid tumor (Figure 1). Immunohistochemical staining showed that the lesions were positive for AE1/AE3, vimentin, cytokeratin 5/6 (CK5/6), calretinin, podoplanin (D2-40), Wilms’ tumor protein (WT-1), p53 (>50%), and Ki-67 (<15%); partially positive for Pax-8; and negative for desmin, estrogen receptor (ER), progesterone receptor (PR), and carcinoembryonic antigen (CEA) (Figure 2). The patient was monitored by computed tomography and serum CA125 level for 49 months with no recurrence.
Figure 1.

Laparoscopic images, with arrows indicating well-differentiated papillary mesothelioma (WDPM).

UT, uterus; MUT, myoma of uterus; AS, ascites; rt FT, right fallopian tube; rt Ov, right ovary; rt BL, right broad ligament; rt UL, right uterosacral ligament.

Figure 2.

Photomicrographs of hematoxylin and eosin (h&e; panels a and b, 200× and 400× magnification, respectively) and immunohistochemical stains (panels c–k, 200× magnification). Positive staining for vimentin (c) and AE1/AE3 (d) illustrated tumor character and epithelial origin; positive results for other stains confirmed a mesothelial proliferation: cytokeratin 5/6 (CK5/6) (e), calretinin (f), podoplanin (D2-40) (g), and Wilms’ tumor protein (WT-1) (h). Staining for p53 was >50% positive (I) and staining for Ki-67 was <15% positive (j). Partly positive staining for Pax-8 (k) was helpful in the differential diagnosis.

Laparoscopic images, with arrows indicating well-differentiated papillary mesothelioma (WDPM). UT, uterus; MUT, myoma of uterus; AS, ascites; rt FT, right fallopian tube; rt Ov, right ovary; rt BL, right broad ligament; rt UL, right uterosacral ligament. Photomicrographs of hematoxylin and eosin (h&e; panels a and b, 200× and 400× magnification, respectively) and immunohistochemical stains (panels c–k, 200× magnification). Positive staining for vimentin (c) and AE1/AE3 (d) illustrated tumor character and epithelial origin; positive results for other stains confirmed a mesothelial proliferation: cytokeratin 5/6 (CK5/6) (e), calretinin (f), podoplanin (D2-40) (g), and Wilms’ tumor protein (WT-1) (h). Staining for p53 was >50% positive (I) and staining for Ki-67 was <15% positive (j). Partly positive staining for Pax-8 (k) was helpful in the differential diagnosis.

Discussion

There are rare case reports of WDPM progressing to true malignant peritoneal mesothelioma. Clinically, WDPM is often discovered incidentally during pelvic examination or surgery. Imaging features of WDPM are not well documented, but complete resection, when possible, usually leads to normal survival.[1,4-6] Genome-wide sequencing analysis shows that WDPM has a genetic profile distinct from that of malignant mesothelioma, with a lack of copy number alterations in genes characteristic of peritoneal and pleural mesothelioma: BAP1, SETD2, PBRM1, SMARCC1, CDKN2A/B, LATS1/2, and NF2.[7,8] Adenomatoid tumors are also relatively uncommon benign tumors of mesothelial origin that usually occur in the male or female genital tract.[9] Although the American Society of Clinical Oncology published a clinical practice guideline on fertility preservation for adults and children with cancer in 2006, which has been updated periodically,[10,11] therapeutic strategies for WDPM with adenomatoid tumor are not currently described. Therefore, treatment that allows patients with WDPM with adenomatoid tumor to become pregnant is a new challenge. Ovulation, good oviduct function, a suitable endometrium for embryo implantation, and appropriate luteal support before and after pregnancy are prerequisites for pregnancy. In the present case, although the patient had natural ovulation, the surface of the right fallopian tube was covered with miliary tumors of different sizes, which may have affected fallopian tube function. Moreover, salpingography showed that one side of the fallopian tube was blocked, which reduced the probability of pregnancy by 50%. Immune and other factors cannot be excluded as possible causes of the patient’s 12-year history of infertility. In vitro fertilization is the first choice for treating infertility. However, it is not known whether the process of oocyte retrieval in a case such as that described here could lead to pelvic tumor spread and whether an invisible tumor implanted on the surface of the ovary could migrate inside the ovary. There are no reports on the effect of estrogen and progesterone on the prognosis of WDPM. Estrogen has been shown to aggravate disease progression in multiple cancer cell lines and mouse models, such as lung cancer, gastric cancer, skin cancer, and others.[12] Therefore, caution is required when considering adding or stimulating the production of supraphysiological estrogen for these patients.

Conclusions

Although our patient’s diagnosis does not affect her daily life, she has been infertile for 12 years and cannot become pregnant using assisted reproductive technology because of the lack of effective radical treatment for WDPM. Over time, ovarian failure may occur and the patient may never achieve fertility. This is an urgent problem that infertility doctors should address. Click here for additional data file. Supplemental material, sj-pdf-1-imr-10.1177_0300060520986680 for Peritoneal well-differentiated papillary mesothelioma associated with infertility in a 37-year-old woman by Bo Pang, Cong Hu, Qian Liu, Jinyu Yu, Zhentong Wei and Xiaowei Yu in Journal of International Medical Research
  12 in total

1.  Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update.

Authors:  Kutluk Oktay; Brittany E Harvey; Ann H Partridge; Gwendolyn P Quinn; Joyce Reinecke; Hugh S Taylor; W Hamish Wallace; Erica T Wang; Alison W Loren
Journal:  J Clin Oncol       Date:  2018-04-05       Impact factor: 44.544

Review 2.  Neoplastic diseases of the peritoneum and mesentery.

Authors:  Patrick D McLaughlin; Antonella Filippone; Michael M Maher
Journal:  AJR Am J Roentgenol       Date:  2013-05       Impact factor: 3.959

3.  Malignant transformation of well-differentiated papillary mesothelioma 13 years after the diagnosis: a case report.

Authors:  Luisa Costanzo; Simone Scarlata; Giuseppe Perrone; Luigi Rossi; Anselmo Papa; Francesco Maria Di Matteo; Giuseppe Tonini; Andrea Onetti Muda; Raffaele Antonelli-Incalzi; Silverio Tomao
Journal:  Clin Respir J       Date:  2013-11-26       Impact factor: 2.570

4.  Well-differentiated papillary mesothelioma of the female peritoneum: a clinicopathologic study of 26 cases.

Authors:  Anais Malpica; Sara Sant'Ambrogio; Michael T Deavers; Elvio G Silva
Journal:  Am J Surg Pathol       Date:  2012-01       Impact factor: 6.394

5.  Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells.

Authors:  Nikolaos Svoronos; Alfredo Perales-Puchalt; Michael J Allegrezza; Melanie R Rutkowski; Kyle K Payne; Amelia J Tesone; Jenny M Nguyen; Tyler J Curiel; Mark G Cadungog; Sunil Singhal; Evgeniy B Eruslanov; Paul Zhang; Julia Tchou; Rugang Zhang; Jose R Conejo-Garcia
Journal:  Cancer Discov       Date:  2016-09-30       Impact factor: 39.397

Review 6.  From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation.

Authors:  Angela D Levy; Javier Arnáiz; Janet C Shaw; Leslie H Sobin
Journal:  Radiographics       Date:  2008 Mar-Apr       Impact factor: 5.333

Review 7.  Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Alison W Loren; Pamela B Mangu; Lindsay Nohr Beck; Lawrence Brennan; Anthony J Magdalinski; Ann H Partridge; Gwendolyn Quinn; W Hamish Wallace; Kutluk Oktay
Journal:  J Clin Oncol       Date:  2013-05-28       Impact factor: 44.544

8.  Adenomatoid tumor of the pleura.

Authors:  Hiroshi Minato; Takayuki Nojima; Nozomu Kurose; Eriko Kinoshita
Journal:  Pathol Int       Date:  2009-08       Impact factor: 2.534

9.  Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum.

Authors:  Young Ki Lee; Hyun Jung Jun; Ji Hae Nahm; Tae Seop Lim; Ji Soo Park; Joong Bae Ahn; Sun Young Rha; Hyun Cheol Chung; Hwa Eun Oh; Ji-Sun Song; Woo Ick Yang; Hyo Song Kim
Journal:  Jpn J Clin Oncol       Date:  2013-08-20       Impact factor: 3.019

10.  Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant Mesothelioma.

Authors:  Raunak Shrestha; Noushin Nabavi; Stanislav Volik; Shawn Anderson; Anne Haegert; Brian McConeghy; Funda Sar; Sonal Brahmbhatt; Robert Bell; Stephane Le Bihan; Yuzhuo Wang; Colin Collins; Andrew Churg
Journal:  Cancers (Basel)       Date:  2020-06-13       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.